Ayalew Tefferi

1 month ago | nature.com | Naseema Gangat |Ayalew Tefferi

Momelotinib, a small-molecule Janus kinase 1 and 2 (JAK1/2) and activin A receptor, type 1 (ACVR1)/activin receptor-like kinase 2 (ALK2) inhibitor, represents an important addition to the treatment armamentarium for myelofibrosis (MF), due to its ability to not only address splenomegaly, and constitutional symptoms but also alleviate anemia [1, 2].

2 months ago | nature.com | Naseema Gangat |Ayalew Tefferi

Venotoclax schedule in acute myeloid leukemia Acute myeloid leukemia (AML) afflicts older individuals (median age 68 years), the majority of whom are unfit to receive intensive induction chemotherapy.

2 months ago | onlinelibrary.wiley.com | Carlo Brugnara |Alessandro Vannucchi |Ayalew Tefferi

• , “ As I Recall the Beginning of the American Journal of Hematology Forty Years Ago ,” American Journal of Hematology ( ): , https://doi.org/10.1002/ajh.24205. • , “ The American Journal of Hematology in 2007 ,” American Journal of Hematology , no. ( ): – , https://doi.org/10.1002/ajh.21160. • and , “ The American Journal of Hematology, 2011 and Beyond ,” American Journal of Hematology , no. ( ): 1, https://doi.org/10.1002/ajh.21951.

Mar 9, 2025 | onlinelibrary.wiley.com | Naseema Gangat |Ayalew Tefferi

Conflicts of Interest N.G. has served on the Advisory Board for DISC Medicine and Agios. References 1, , , et al., “Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients,” Mayo Clinic Proceedings 90, no. 12 (2015): 1623–1638, https://doi.org/10.1016/j.mayocp.2015.08.022. 2, , , et al., “One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience,” Mayo Clinic Proceedings 87, no. 1 (2012): 25–33.

Mar 3, 2025 | nature.com | Daniel A. Arber |Ayalew Tefferi |Alessandro Vannucchi |Tiziano Barbui

AbstractA lively discussion persists regarding the diagnostic criteria for essential thrombocythemia (ET), primary myelofibrosis (PMF) and polycythemia vera (PV), particularly in relation to early/pre-fibrotic myelofibrosis (pre-PMF), a disease entity initially introduced in 2001 by the 3rd edition of the World Health Organization (WHO) classification. The definition and criteria used to diagnose pre-PMF have been progressively modified over time.